Of course the ChatGPT dog cancer vaccine spawned a startup
An Australian entrepreneur has launched Gamgee, a startup using AI to develop personalized mRNA cancer vaccines for pets and humans.
- Gamgee was founded by Paul Conyngham after using AI tools to design a personalized mRNA cancer vaccine for his dog, Rosie.
- The startup initially targets pets but plans to expand to human therapies using AI and mRNA technology.
- Gamgee has not yet published peer-reviewed clinical data, raising questions about its scientific validation.
- The company reflects a broader trend of AI-driven startups entering personalized medicine and drug discovery.
Paul Conyngham, an Australian entrepreneur, has launched Gamgee, a startup focused on developing personalized mRNA cancer vaccines. The company initially gained attention for using AI tools like ChatGPT and Grok to design a vaccine for his dog, Rosie, who reportedly recovered from cancer. Gamgee now aims to expand its AI-driven approach to treat a broader range of diseases across multiple species, including humans.
The startup’s technology leverages mRNA sequencing and AI to tailor treatments to individual patients, a method that has shown promise in early-stage veterinary applications. While the initial focus was on pets, Gamgee’s long-term vision includes human therapies, positioning the company at the intersection of AI, genomics, and personalized medicine. The launch follows widespread interest in AI’s role in accelerating drug discovery and medical innovation.
Conyngham’s project has sparked both excitement and skepticism, with critics questioning the scientific rigor behind AI-generated medical solutions. Gamgee has not yet published peer-reviewed data, raising questions about the reproducibility and efficacy of its approach. Despite this, the startup’s ambitious goals reflect a growing trend of AI-driven biotech startups pushing the boundaries of traditional medicine.
Highlights the potential of AI in accelerating drug discovery and personalized medicine workflows.
Demonstrates a new business model in biotech, blending AI with mRNA technology for commercial opportunities.
Shows investor interest in AI-driven biotech startups, even with early-stage and unvalidated claims.
Offers a case study in interdisciplinary innovation, combining AI, genomics, and veterinary medicine.
Raises public awareness of AI’s role in medical breakthroughs and the ethical considerations of unproven treatments.
- mRNA
- Messenger RNA, a molecule that carries genetic instructions for making proteins, used in vaccines to trigger immune responses.
- personalized medicine
- Medical treatment tailored to an individual’s genetic, environmental, and lifestyle factors.
AI code-testing startup Blacksmith’s valuation jumps almost 10x in less than a year
StartupsNaïve raises $28.5M to automate the grunt work of setting up and running a company
StartupsEx-Spotify employees raise $10M to bring the AI behind its recommendations to e-commerce
StartupsJeff Dean and other top AI researchers are leaving Google to launch their own startup
StartupsGoogle’s Top AI Brains Are Leaving to Launch Discovery Loop
The Role of Artificial Intelligence In Access - pharmaceuticalcommerce.com
Google News reports on the role of artificial intelligence in improving access to pharmaceuticals, citing a recent study.
HardwareGoogle unveils Pixel 11 lineup, new AirTag rival, and Gemini features at Made by Google 2026
Google introduced the Pixel 11 lineup alongside a new tracker device to rival Apple's AirTag, plus enhanced Gemini AI features at its Made by Google 2026 event.
Patients wary of government, companies pushing AI as a rural healthcare solution - South Dakota Searchlight
Rural patients in South Dakota express distrust toward AI-driven healthcare solutions promoted by government agencies and private companies.
AI ToolsPutting sign language AI into users’ hands
DeepMind unveiled SL2T, a model that converts sign language to text in real time, aiming to improve accessibility for Deaf and hard of hearing users.
AI ToolsLFM2.5-VL-3B for Better and Faster Vision Capabilities for the Edge
Liquid AI released LFM2.5-VL-3B, a 3-billion-parameter vision-language model optimized for edge devices, promising faster inference and lower resource usage than prior models.
How OneAdvanced deployed over 50 AI agents on UK-sovereign AWS - Amazon Web Services (AWS)
OneAdvanced has deployed more than 50 AI agents on UK-sovereign AWS infrastructure, leveraging Amazon's cloud for compliance and scalability.